Ensign Peak Advisors’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Ensign Peak Advisors’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-139,196	Closed	-$564K	–	1773
2023 Q4	$564K	Hold	139,196	–	–	﹤0.01%	1635
2023 Q3	$374K	Sell	139,196 -3,402	-2%	-$13.3K	﹤0.01%	1655
2023 Q2	$1.33M	Hold	142,598	–	–	﹤0.01%	1043
2023 Q1	$1.27M	Hold	142,598	–	–	﹤0.01%	1061
2022 Q4	$710K	Hold	142,598	–	–	﹤0.01%	1441
2022 Q3	$827K	Hold	142,598	–	–	﹤0.01%	1177
2022 Q2	$788K	Sell	142,598 -107,402	-43%	-$887K	﹤0.01%	1246
2022 Q1	$2.88M	Hold	250,000	–	–	0.01%	742
2021 Q4	$3.17M	Buy	+250,000	New	+$3.77M	0.01%	805

Ensign Peak Advisors's THRX Position: Q1 2024 in Review

Ensign Peak Advisors sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 139,196 shares — an estimated $564K sold.

Ensign Peak Advisors first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $3.17M in Q4 2021. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

Ensign Peak Advisors reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Ensign Peak Advisors sold 139,196 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $564K.
Ensign Peak Advisors first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
Ensign Peak Advisors's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $3.17M in Q4 2021.
1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Ensign Peak Advisors's 13F filing for Q1 2024, filed 14 May 2024.